Vivus Wins Its First Fda Drug Approval

The FDA approved a drug to treat erectile dysfunction from Vivus that would compete against Viagra, Cialis and Levitra.

Topics:  fda   vivus   viagra   cialis   levitra   drug   
BING NEWS:
  • Vivus Wins FDA Approval for Obesity Drug, After Long, Messy Day
    Vivus has been pushing for more than two years to get its new obesity drug cleared for sale by the FDA, and after one last long, confusing day, it finally got its wish. The FDA said today that the Mountain View, CA-based company (NASDAQ: VVUS) has gotten ...
    07/17/2012 - 12:32 pm | View Link
  • Vivus Wins FDA Approval
    MINYANVILLE ORIGINAL Vivus (VVUS) shareholders got a piece of good news late last week when the Food and Drug Administration approved the ... a decision on market clearance in April but the FDA delayed doing so until July 17. "The majority of the value ...
    04/30/2012 - 9:07 am | View Link
  • Vivus' Erectile Dysfunction Drug Stendra Wins FDA Approval
    Law360, New York (April 27, 2012, 8:00 PM ET) -- The U.S. Food and Drug Administration on Friday approved Vivus Inc.'s erectile dysfunction pill Stendra, the first erectile dysfunction treatment to be allowed for use in the U.S. in a decade and the first ...
    04/27/2012 - 1:00 pm | View Link
  • Vivus Obesity Pill Wins FDA Panel Nod; NeuroSearch Surges
    Trading in Vivus stock was halted yesterday before the FDA panel vote. NeuroSearch, which is developing tesofensine for obesity, climbed 5.6 percent to 17 kroner and Novo Nordisk, which is studying its Victoza diabetes drug as a weight-loss treatment ...
    02/22/2012 - 11:00 am | View Link
  • Vivus' Weight-Loss Drug Faces Key U.S. Test
    If Qnexa wins the FDA's green light, that could more than double. Analysts estimate Vivus' drug could take in nearly $689 million in sales by 2014, according to consensus forecast data from Thomson Reuters. It would be the second U.S. drug for the biotech ...
    07/14/2010 - 1:00 pm | View Link
  • More
BING SEARCH:
  • Qsymia Review | How It works, In-Depth Reviews, FDA Approved?
    Conclusion. Qsymia or Qnexa is a weight loss drug that passed the FDA approval process in July, 2012. The drug can cause heart-related side effects and loss of ...
    09/1/2014 - 8:58 pm | View Website
  • VVUS
    Up to date analysis of Vivus, Inc. (VVUS) and its stock by hedge fund managers and industry experts. Find out what Vivus, Inc. is saying about its business from the ...
    09/1/2014 - 8:36 pm | View Website
  • Breaking News – RTTNews
    Swiss drug maker Novartis AG (NVS) said Saturday its investigational heart failure drug LCZ696 was found to be superior to enalapril on key endpoints in a heart ...
    09/1/2014 - 12:23 pm | View Website
  • Project FDA Report 5 | Stifling New Cures: The True Cost ...
    Avik Roy, Project FDA Report 5, April 2012. ... Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials . Avik S. A. Roy, Senior Fellow, Manhattan Institute ...
    08/31/2014 - 4:27 pm | View Website
  • VIVUS Qsymia Patents: Intellectual Property House of Cards ...
    Robert Diggs Deeper: Is Vivus Worth more than $0.24 Per Share? What is new in the report? A prior art challenge I filed against a pending Qsymia patent in ...
    08/30/2014 - 7:42 pm | View Website
  • More
Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More U.s. News